Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Limited Reinfusion of CD34+ Cells
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2017
At a glance
- Drugs Angiotensin-1-7 (Primary)
- Indications Thrombocytopenia
- Focus Adverse reactions; Therapeutic Use
- Acronyms TXA127-PBSC
- Sponsors Biotest Pharmaceuticals
- 10 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.
- 10 Oct 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 10 Jun 2017 Biomarkers information updated